Related Experiment Video
Updated: Mar 30, 2026
10:41
Cardiac Spheroids as in vitro Bioengineered Heart Tissues to Study Human Heart Pathophysiology
Published on: January 23, 2021
8.6K
Circulating Stromal Cell-Derived Factor 1α Levels in Heart Failure: A Matter of Proper Sampling
Lesley Baerts1, Yannick Waumans1, Inger Brandt2
1Laboratory of Medical Biochemistry, University of Antwerp, Antwerp, Belgium.
Plos One
|November 7, 2015
Summary
Stromal cell-derived factor 1α (SDF1α) levels in heart failure patients are higher when collected with a DPP4 inhibitor. This improves biomarker accuracy for cardiac disease research.
Area of Science:
- Biochemistry
- Cardiology
- Biomarker Discovery
Background:
- Stromal cell-derived factor 1α (SDF1α, CXCL12) is a potential biomarker for cardiac diseases.
- Truncated SDF1α forms alter biological activity, complicating interpretation.
- Dipeptidyl peptidase-4 (DPP4) degrades SDF1α.
Purpose of the Study:
- To investigate the impact of DPP4 on SDF1α immunoreactivity.
- To evaluate the effect of DPP4 inhibition during sample collection on measured SDF1α levels.
- To assess SDF1α levels in heart failure patients with varying left ventricular function.
Main Methods:
- Studied SDF1α immunoreactivities with three immunoassays.
- Incubated SDF1α with DPP4 and serum to assess degradation.
- Measured SDF1α and DPP4 activity in heart failure patients using optimized sampling with DPP4 inhibitor.
Main Results:
- DPP4 incubation caused a significant loss of SDF1α immunoreactivity.
- SDF1α levels were significantly higher in heart failure patients with severe left ventricular dysfunction.
- DPP4 activity was decreased in patients with high SDF1α levels, suggesting feedback inhibition.
Conclusions:
- Recommend collecting samples for SDF1α analysis with a DPP4 inhibitor.
- Higher SDF1α levels were observed in specific heart failure subgroups with DPP4 inhibition.
- Further research is needed on the clinical relevance of SDF1α in cardiac disease.
More Related Videos
08:43Isolation of Endothelial Progenitor Cells from Healthy Volunteers and Their Migratory Potential Influenced by Serum Samples After Cardiac Surgery
Published on: February 14, 2017
11.6K
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
5.9K
Related Concept Videos
01:29Heart Failure II: Pathophysiology
1.4K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K
01:01Regulation of Hematopoietic Stem Cells
4.4K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.4K
01:17Pathophysiology of Heart Failure
4.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.6K
01:27Heart Failure I: Introduction
1.3K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.3K
01:30Heart Failure IV: Classification and Diagnostic Evaluation
594
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
594
01:22Heart Failure VI: Adjunct Therapies
568
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
568